An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

Yanmei Hu, Rami Musharrafieh, Chunlong Ma, Jiantao Zhang, Donald F. Smee, William F. DeGrado, Jun Wang

Research output: Research - peer-reviewArticle

  • 4 Citations

Abstract

Adamantanes such as amantadine (1) and rimantadine (2) are FDA-approved anti-influenza drugs that act by inhibiting the wild-type M2 proton channel from influenza A viruses, thereby inhibiting the uncoating of the virus. Although adamantanes have been successfully used for more than four decades, their efficacy was curtailed by emerging drug resistance. Among the limited number of M2 mutants that confer amantadine resistance, the M2-V27A mutant was found to be the predominant mutant under drug selection pressure, thereby representing a high profile antiviral drug target. Guided by molecular dynamics simulations, we previously designed first-in-class M2-V27A inhibitors. One of the potent lead compounds, spiroadamantane amine (3), inhibits both the M2-WT and M2-V27A mutant with IC50 values of 18.7 and 0.3 μM, respectively, in in vitro electrophysiological assays. Encouraged by these findings, in this study we further examine the in vitro and in vivo antiviral activity of compound 3 in inhibiting both amantadine-sensitive and -resistant influenza A viruses. Compound 3 not only had single to sub-micromolar EC50 values against M2-WT- and M2-V27A-containing influenza A viruses in antiviral assays, but also rescued mice from lethal viral infection by either M2-WT- or M2-V27A-containing influenza A viruses. In addition, we report the design of two analogs of compound 3, and one was found to have improved in vitro antiviral activity over compound 3. Collectively, this study represents the first report demonstrating the in vivo antiviral efficacy of inhibitors targeting M2 mutants. The results suggest that inhibitors targeting drug-resistant M2 mutants are promising antiviral drug candidates worthy of further development.

LanguageEnglish (US)
Pages45-54
Number of pages10
JournalAntiviral Research
Volume140
DOIs
StatePublished - Apr 1 2017

Fingerprint

Amantadine
Influenza A virus
Antiviral Agents
In Vitro Techniques
Adamantane
Pharmaceutical Preparations
Virus Uncoating
Rimantadine
Virus Diseases
Molecular Dynamics Simulation
Drug Delivery Systems
Drug Resistance
Human Influenza
Amines
Protons
Pressure
Lead

Keywords

  • Antiviral
  • Drug resistance
  • Influenza virus
  • M2 proton channel
  • Spiroadamantane
  • V27A

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. / Hu, Yanmei; Musharrafieh, Rami; Ma, Chunlong; Zhang, Jiantao; Smee, Donald F.; DeGrado, William F.; Wang, Jun.

In: Antiviral Research, Vol. 140, 01.04.2017, p. 45-54.

Research output: Research - peer-reviewArticle

Hu, Yanmei ; Musharrafieh, Rami ; Ma, Chunlong ; Zhang, Jiantao ; Smee, Donald F. ; DeGrado, William F. ; Wang, Jun. / An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. In: Antiviral Research. 2017 ; Vol. 140. pp. 45-54
@article{26886a4fdfa748b5a51543ec9744a47a,
title = "An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses",
abstract = "Adamantanes such as amantadine (1) and rimantadine (2) are FDA-approved anti-influenza drugs that act by inhibiting the wild-type M2 proton channel from influenza A viruses, thereby inhibiting the uncoating of the virus. Although adamantanes have been successfully used for more than four decades, their efficacy was curtailed by emerging drug resistance. Among the limited number of M2 mutants that confer amantadine resistance, the M2-V27A mutant was found to be the predominant mutant under drug selection pressure, thereby representing a high profile antiviral drug target. Guided by molecular dynamics simulations, we previously designed first-in-class M2-V27A inhibitors. One of the potent lead compounds, spiroadamantane amine (3), inhibits both the M2-WT and M2-V27A mutant with IC50 values of 18.7 and 0.3 μM, respectively, in in vitro electrophysiological assays. Encouraged by these findings, in this study we further examine the in vitro and in vivo antiviral activity of compound 3 in inhibiting both amantadine-sensitive and -resistant influenza A viruses. Compound 3 not only had single to sub-micromolar EC50 values against M2-WT- and M2-V27A-containing influenza A viruses in antiviral assays, but also rescued mice from lethal viral infection by either M2-WT- or M2-V27A-containing influenza A viruses. In addition, we report the design of two analogs of compound 3, and one was found to have improved in vitro antiviral activity over compound 3. Collectively, this study represents the first report demonstrating the in vivo antiviral efficacy of inhibitors targeting M2 mutants. The results suggest that inhibitors targeting drug-resistant M2 mutants are promising antiviral drug candidates worthy of further development.",
keywords = "Antiviral, Drug resistance, Influenza virus, M2 proton channel, Spiroadamantane, V27A",
author = "Yanmei Hu and Rami Musharrafieh and Chunlong Ma and Jiantao Zhang and Smee, {Donald F.} and DeGrado, {William F.} and Jun Wang",
year = "2017",
month = "4",
doi = "10.1016/j.antiviral.2017.01.006",
volume = "140",
pages = "45--54",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

AU - Hu,Yanmei

AU - Musharrafieh,Rami

AU - Ma,Chunlong

AU - Zhang,Jiantao

AU - Smee,Donald F.

AU - DeGrado,William F.

AU - Wang,Jun

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Adamantanes such as amantadine (1) and rimantadine (2) are FDA-approved anti-influenza drugs that act by inhibiting the wild-type M2 proton channel from influenza A viruses, thereby inhibiting the uncoating of the virus. Although adamantanes have been successfully used for more than four decades, their efficacy was curtailed by emerging drug resistance. Among the limited number of M2 mutants that confer amantadine resistance, the M2-V27A mutant was found to be the predominant mutant under drug selection pressure, thereby representing a high profile antiviral drug target. Guided by molecular dynamics simulations, we previously designed first-in-class M2-V27A inhibitors. One of the potent lead compounds, spiroadamantane amine (3), inhibits both the M2-WT and M2-V27A mutant with IC50 values of 18.7 and 0.3 μM, respectively, in in vitro electrophysiological assays. Encouraged by these findings, in this study we further examine the in vitro and in vivo antiviral activity of compound 3 in inhibiting both amantadine-sensitive and -resistant influenza A viruses. Compound 3 not only had single to sub-micromolar EC50 values against M2-WT- and M2-V27A-containing influenza A viruses in antiviral assays, but also rescued mice from lethal viral infection by either M2-WT- or M2-V27A-containing influenza A viruses. In addition, we report the design of two analogs of compound 3, and one was found to have improved in vitro antiviral activity over compound 3. Collectively, this study represents the first report demonstrating the in vivo antiviral efficacy of inhibitors targeting M2 mutants. The results suggest that inhibitors targeting drug-resistant M2 mutants are promising antiviral drug candidates worthy of further development.

AB - Adamantanes such as amantadine (1) and rimantadine (2) are FDA-approved anti-influenza drugs that act by inhibiting the wild-type M2 proton channel from influenza A viruses, thereby inhibiting the uncoating of the virus. Although adamantanes have been successfully used for more than four decades, their efficacy was curtailed by emerging drug resistance. Among the limited number of M2 mutants that confer amantadine resistance, the M2-V27A mutant was found to be the predominant mutant under drug selection pressure, thereby representing a high profile antiviral drug target. Guided by molecular dynamics simulations, we previously designed first-in-class M2-V27A inhibitors. One of the potent lead compounds, spiroadamantane amine (3), inhibits both the M2-WT and M2-V27A mutant with IC50 values of 18.7 and 0.3 μM, respectively, in in vitro electrophysiological assays. Encouraged by these findings, in this study we further examine the in vitro and in vivo antiviral activity of compound 3 in inhibiting both amantadine-sensitive and -resistant influenza A viruses. Compound 3 not only had single to sub-micromolar EC50 values against M2-WT- and M2-V27A-containing influenza A viruses in antiviral assays, but also rescued mice from lethal viral infection by either M2-WT- or M2-V27A-containing influenza A viruses. In addition, we report the design of two analogs of compound 3, and one was found to have improved in vitro antiviral activity over compound 3. Collectively, this study represents the first report demonstrating the in vivo antiviral efficacy of inhibitors targeting M2 mutants. The results suggest that inhibitors targeting drug-resistant M2 mutants are promising antiviral drug candidates worthy of further development.

KW - Antiviral

KW - Drug resistance

KW - Influenza virus

KW - M2 proton channel

KW - Spiroadamantane

KW - V27A

UR - http://www.scopus.com/inward/record.url?scp=85009893948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009893948&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2017.01.006

DO - 10.1016/j.antiviral.2017.01.006

M3 - Article

VL - 140

SP - 45

EP - 54

JO - Antiviral Research

T2 - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -